- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
A Bispecific Immunotherapy for the Treatment of Melanoma
Mark R. Middleton, MD, PhD, discusses the results of a phase I/IIa trial of IMCgp100, a bispecific immunotherapy, for the treatment of patients with melanoma.
Mark R. Middleton, MD, PhD, a professor of experimental cancer medicine at the University of Oxford, discusses the results of a phase I/IIa trial of IMCgp100, a bispecific immunotherapy, for the treatment of patients with melanoma.
<<<